Therefore, it may be crucial to identify available modalities with RKIP-promoting activities, or develop new agents targeting RKIP overexpression, that can be used alone or in combination, to abolish the cancer-related properties listed above and resulting in novel successful therapeutic approaches for all cancers. This evidence concerns the gene PEBP1 and cancer.